Vraylar vs Abilify: Which Works Better for Bipolar Disorder?

Bipolar disorder is a chronic mental health condition characterized by significant shifts in mood, energy levels, and activity. These changes may include episodes of mania or hypomania and episodes of depression. 

Choosing an appropriate medication for this medical condition is essential to ensure its long-term management. Psychiatrists may prescribe atypical antipsychotic medications such as Abilify (Aripiprazole) and Vraylar (Cariprazine) as part of a bipolar disorder treatment plan. 

Both medications affect dopamine and serotonin receptors in the brain, which may help manage symptoms associated with bipolar disorder. There is no single medication that works best for everyone. The most appropriate treatment depends on factors such as symptom pattern, treatment history, other medical conditions, side effect tolerance, and a psychiatrist’s clinical assessment. 

Vraylar vs Abilify: Key Differences at a Glance

Patients and caregivers often compare Vraylar and Abilify when discussing treatment options for bipolar disorder. While both medications are FDA-approved for certain bipolar-related indications, they differ in their approved uses, dosing, side-effect profiles, and clinical characteristics. 

Here are the major differences between Vraylar and Ablify for bipolar disorder:

Feature	Vraylar	Abilify
Active Ingredient	Cariprazine	Aripiprazole
Mechanism of Action	Vraylar (cariprazine) is a dopamine D3- and D2-receptor partial agonist with a higher affinity for D3 receptors, which may contribute to its effects on mood and cognition.	Abilify (aripiprazole) is a dopamine D2- and serotonin 5-HT1A-receptor partial agonist and a 5-HT2A antagonist. Its activity at these receptors may help manage symptoms associated with bipolar disorder and other psychiatric conditions.
Dosage forms	It comes in the form of an oral capsule that has to be swallowed as a whole, once a day.	It comes in various forms like oral tablets with or without a sensor, oral disintegrating tablets, oral liquid, fast-acting intramuscular injection, and long-acting intramuscular injections given once or twice a month.
Available strengths	0.5, 0.75, 1.5, 3, 4.5, and 6 mg capsules	2, 5, 10, 15, 20, and 30 mg tablets
FDA-approved uses/indications	Vraylar is approved for: Schizophrenia in adults, Short-term treatment for adults experiencing manic or mixed episodes related to Bipolar I Disorder, Treatment of depressive phases linked to Bipolar I Disorder in adults (bipolar depression), Adjunctive therapy to antidepressants for major depressive disorder in adults	Management of sudden manic and mixed mood episodes in individuals with Bipolar I Disorder. Maintenance treatment of Bipolar I Disorder and Tourette’s disorder in 6- to 17-year-old patients. Schizophrenia in at least 13-year-old patients.Irritability symptom of autistic disorder in 6-18-year-old patients.Major depressive disorder in adults, in combination with an antidepressant.
Off-label uses	Treatment-resistant depression, schizoaffective disorder, and anxiety disorders.	Obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar II disorder, and sleep disorders.
Maintenance Treatment	Not specifically FDA-approved for maintenance treatment of Bipolar I Disorder	FDA-approved for maintenance treatment of Bipolar I Disorder
Risk of Weight Gain	Generally associated with relatively modest weight gain	Generally associated with relatively modest weight gain
Risk of Sedation	Sleepiness or sedation may occur in some patients	May be less likely to cause sedation in some patients, though individual responses vary
Cost	Generally higher cost because it is available primarily as a brand-name medication	Generic aripiprazole is available and may reduce treatment costs

The information above is intended for educational purposes only. Medication selection should be based on a psychiatrist’s evaluation of symptoms, treatment history, medical conditions, and individual response to therapy.

Vraylar or Abilify: Which Works Better for Bipolar Disorder?

There is no single medication that works best for every person with bipolar disorder. The most appropriate treatment depends on factors such as symptom type, treatment history, side-effect tolerance, other medical conditions, and a psychiatrist’s clinical assessment.  

Patients interested in learning more about Vraylar’s uses, benefits, and dosing can read our detailed guide on Vraylar (Cariprazine): Benefits, Dosage.

Vraylar may be considered in patients who: 

• Experience bipolar depression as a significant symptom
• Have not achieved adequate symptom control with previous treatment approaches
• Require treatment for depressive episodes associated with Bipolar I Disorder, and may also need management of manic or mixed episodes
• Are concerned about weight-related side effects 

Abilify may be considered in patients who: 

• Experiencing mania or hypomania as the primary symptom
• Require a medication approved for maintenance treatment of Bipolar I Disorder
• Prefer the availability of injectable treatment options
• Are interested in lower-cost generic treatment options
• Prefer a medication with a long track record of clinical use and prescribing experience 

A psychiatrist can help determine which medication is most appropriate based on an individual’s symptoms, medical history, treatment goals, and response to previous therapies.

Vraylar vs Abilify Side Effects

Direct head-to-head clinical studies are comparing Vraylar vs Abilify side effects. Both medicines share similar side effects, including:

• Nausea or vomiting
• Dizziness
• Insomnia
• Constipation
• Akathisia (inner restlessness, or difficulty remaining seated).

The likelihood and severity of side effects can vary from person to person.

Abilify side effects are:

• Nausea or vomiting
• Dizziness
• Constipation
• Anxiety
• Insomnia
• Restlessness
• Headache
• Upper respiratory illness
• Blurred vision.

For children, appetite change, weight gain, fatigue, muscle stiffness, and drooling are also common.

Adults who take Vraylar commonly experience: 

• Slowed or abnormal body movements 
• Tremors
• Akathisia (inner restlessness, or difficulty remaining seated) 
• Constipation or Indigestion 
• Nausea
• Sleepiness or drowsiness 
• Increased appetite.

Both medications may also cause serious side effects, including metabolic changes, involuntary movements (such as tardive dyskinesia), low white blood cell counts, and neuroleptic malignant syndrome, although these events are uncommon. Patients should seek medical attention if they experience severe, persistent, or unusual symptoms. 

Dosage, Cost, and Treatment Considerations

Dosage for Vraylar:

For bipolar depression:

• Recommended starting dose: 1.5 mg daily
• The dose may be increased to 3 mg once daily based on clinical response and tolerability 

For manic or mixed episodes associated with Bipolar I Disorder: 

• Recommended dose range: 3 to 6 mg once daily.

Dosage for Abilify:

For Bipolar I Disorder (manic or mixed episodes) in adults:

• Recommended starting dose: 10-15 mg once daily
• Recommended target dose: 15 mg daily either alone or in combination with other lithium or valproate 
• Maximum dose: 30 mg once daily.

Cost Comparison:

Vraylar is generally more expensive than Abilify because it is primarily available as a brand-name medication. However, eligible patients may be able to reduce out-of-pocket costs through manufacturer assistance or savings programs. 

Generic cariprazine is not widely available, whereas generic aripiprazole is available and may help lower treatment costs. 

Insurance coverage requirements vary by plan. In some cases, Vraylar may require prior authorization, while generic aripiprazole is often covered more broadly due to its lower cost. 

Treatment Considerations:

Vraylar may be considered when: 

• Bipolar depression is a significant concern 
• Treatment is needed for depressive episodes associated with Bipolar I Disorder and manic or mixed episodes 
• Concerned about weight gain.
• Previous treatment approaches have not provided adequate symptom control 

Abilify may be considered when: 

• Mania or hypomania is a primary symptom
• Maintenance treatment of Bipolar I Disorder is an important goal
• Injectable treatment options are preferred
• Lower-cost generic treatment options are desired
• A medication with extensive long-term clinical use is preferred 

Key Takeaways

Vraylar (cariprazine) and Abilify (aripiprazole) are atypical antipsychotic medications used to treat Bipolar I Disorder.

Both medications are FDA-approved for manic or mixed episodes associated with Bipolar I Disorder. Vraylar is also FDA-approved for bipolar depression in adults.

Generic aripiprazole is available, while generic cariprazine is not widely available.

Abilify is FDA-approved for maintenance treatment of Bipolar I Disorder and is available in multiple formulations, including injectable options.

Abilify generally reaches steady-state concentrations faster than Vraylar, which has long-lasting active metabolites.

The most appropriate treatment depends on an individual’s symptoms, treatment goals, medical history, side-effect profile, and the psychiatrist’s assessment.

FAQs

Read more related blogs:

Vraylar (Cariprazine): Benefits | Dosage & Side Effects

See more

References:

https://www.vraylar.com/

https://www.abilify.com/